Mucormycosis, or zygomycotic or black fungus, is a fungal infection caused by a group of molds called mucoromycetes. It is the third most common invasive fungal disease after candidiasis and aspergillosis. Mainly caused by contact in the environment with fungal spores. Types of mucormycosis are Disseminated Mucormycosis, Pulmonary (lung) mucormycosis, Rhino cerebral (sinus and brain) Mucormycosis, Cutaneous (skin) Mucormycosis, Gastrointestinal Mucormycosis, Diagnosis mainly depends on biopsy, histological examination, CT scan, or MRI. Early diagnosis, complete removal of infected tissues, and early administration of active antifungal agents allow us to treat Mucormycosis by using different adjunctive therapies. In the pandemic of COVID due to exposure to various irrational and immunosuppressant's, Mucormycosis cases are in great extent, and due to this, the main role of the clinical pharmacist is to maintain drug therapy through medication therapy management, which involves drug dosing regimens and the correlation of drug therapy with other risk factors. This review highlights the indispensable role that clinical pharmacists play in the early diagnosis, treatment, and overall management of mucormycosis, with a focus on rhino-cerebral mucormycosis.